Acute coronary syndrome: are intervention and IIb/IIIa platelet inhibitors epiphenomena?

被引：0
|
作者：
Jackson, G
机构：
来源：
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | 2001年 / 55卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：351 / 352
页数：2
相关论文
共 50 条
  • [41] Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: A review
    Truong, KM
    Amankwa, K
    Kucukarslan, S
    CLINICAL THERAPEUTICS, 2001, 23 (08) : 1145 - 1165
  • [42] Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes
    Bell, DM
    PHARMACOTHERAPY, 1999, 19 (09): : 1086 - 1093
  • [43] Safety of glycoprotein IIb/IIIa inhibitors in patients under therapeutic hypothermia admitted for an acute coronary syndrome
    Jimenez-Britez, Gustavo
    Freixa, Xavier
    Flores, Eduardo
    Penela, Diego
    Hernandez-Enriquez, Marco
    San Antonio, Rodolfo
    Caixal, Gala
    Garcia, John
    Roque, Merce
    Martin, Victoria
    Brugaletta, Salvatore
    Masotti, Monica
    Sabate, Manel
    RESUSCITATION, 2016, 106 : 108 - 112
  • [44] Management of intermediate coronary syndrome: Role of conservative treatment, glycoprotein IIb/IIIa receptor inhibitors, and direct intervention
    Robertson, GC
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (5A): : 21B - 26B
  • [45] Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
    Topol, E
    Califf, R
    Simoons, M
    Diaz, R
    Paolasso, E
    Klein, W
    Boland, J
    DeBacker, G
    Armstrong, P
    Corbalan, R
    Isaza, D
    Widimsky, P
    Urrutia, C
    Luomanmäki, K
    Vahanian, A
    Karsch, K
    Cokkinos, D
    Karatasakis, G
    Toutouzas, P
    Rodas, M
    Keltai, M
    Chierchia, S
    Silva, E
    Erikssen, J
    Ruzyllo, W
    Stepinska, J
    Ribeiro, VD
    Fernandez-Ortiz, A
    Macaya, C
    Goy, J
    Deckers, J
    Skene, A
    Wilcox, R
    Guerci, A
    Harrington, R
    Hochman, J
    Holmes, D
    Kleiman, N
    Kopecky, S
    Lee, K
    Lincoff, A
    Ohman, E
    Pepine, C
    Isea, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (07): : 436 - 443
  • [46] The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era
    Adelman, AG
    Caramori, PRA
    Cohen, EA
    Chisholm, RJ
    Cote, G
    Ducas, J
    O'Neill, BJ
    Tcheng, JE
    CANADIAN JOURNAL OF CARDIOLOGY, 1998, 14 (08) : 1057 - 1066
  • [47] Platelet glycoprotein (GP) IIb/IIIa is associated with platelet aggregation in coronary lesions underlying acute coronary syndromes
    Shinsato, T
    Naruko, T
    Ueda, M
    Haze, K
    Itoh, A
    Otsuka, M
    Sakanoue, Y
    Ikura, Y
    Ogami, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 317S - 317S
  • [48] Risks and benefits of glycoprotein IIb/IIIa antagonists in acute coronary syndrome
    Latour-Pérez, J
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (04) : 472 - 479
  • [49] Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function
    Kereiakes, Dean J.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2006, 7 : S3 - S11
  • [50] Platelet Aggregation Inhibition with Glycoprotein IIb–IIIa Inhibitors
    George Proimos
    Journal of Thrombosis and Thrombolysis, 2001, 11 : 99 - 110
12345